Radiation Segmentectomy for Hepatocellular Carcinoma

Curr Oncol. 2024 Jan 23;31(2):617-628. doi: 10.3390/curroncol31020045.ABSTRACTThe application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCLC) paradigm will be highlighted. RADSEG outcomes concerning safety and efficacy will be explored and compared with traditional locoregional cancer treatments like trans-arterial chemoembolization (TACE), percutaneous thermal ablation, and surgical resection, with an eye on future directions and considerations.PMID:38392039 | PMC:PMC10888093 | DOI:10.3390/curroncol31020045
Source: Current Oncology - Category: Cancer & Oncology Authors: Source Type: research